Advanced Solid Tumor Clinical Trial
Official title:
A Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR-A1403 With Intravenous Infusion in Patients With Advanced Solid Tumors
Verified date | January 2019 |
Source | Jiangsu HengRui Medicine Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
SHR-A1403 is a humanized IgG2, anti-C-Met monoclonal antibody conjugated to microtubule inhibitor (c-Met ADC).The aim of this study is to assess the safety and tolerability of SHR-A1403,to define the dose limited toxicity(DLT)and the maximum tolerated dose (MTD),to evaluate the pharmacokinetics of SHR-A1403,to assess the antitumor activity of SHR-A1403 in patients with advanced solid tumors preliminarily and to recommend the reasonable dosage regimen of SHR-A1403 for the follow-up clinical trial.
Status | Completed |
Enrollment | 9 |
Est. completion date | May 7, 2020 |
Est. primary completion date | December 30, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at both the Screening and baseline visits; - Life expectancy =12 weeks - Diagnosed (histologically or cytologically) with solid tumors and documented as advanced or metastatic disease for which there is no known effective anti-tumor treatment (refractory to or relapsed from standard therapies); - Subjects must have measurable lesion(s) per RECIST v1.1 guideline at the Screening visit. - Adequate laboratory parameters during the Screening Period as evidenced by: - Absolute neutrophil count (ANC)=1.5×109/L (1,500/mm3); - Platelets =100×109/L (100,000/mm3); - Hemoglobin (Hgb) =9.0 g/dL (90 g/L); - Albumin levels =2.8 g/dL; - Total bilirubin =1.5×ULN (=3×ULN for subjects with liver metastases) - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) - 2.5×ULN; for subjects with liver metastases, ALT and AST =5×ULN; - Serum creatinine =1.5×ULN or creatinine clearance =50 mL/min based on Cockcroft-Gault equation; - Subjects must have a washout period =4 weeks since the last dose of cytotoxic chemotherapy,non-cytotoxic chemotherapy(including any previous TKI treatment), any investigational therapy, any prior immuno-oncology or monoclonal antibody products administered and =6 weeks since the last dose of chemotherapy of mitomycin C or nitrosoureas prior to the first dose of SHR-A1403; - Pregnancy and Contraception: - Female subjects agree not to be pregnant or lactating from beginning of the study screening until 6 months after receiving the last treatment; - Male and female subjects and their sexual partners are willing and able to employ a highly effective method of birth control/contraception to prevent pregnancy from beginning of the study screening until 6 months after receiving the last treatment of study drug; - A highly effective method of contraception is defined as one that results in a low failure rate (i.e., less than 1% per year, when used consistently and correctly); - Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to initiation of treatment and not be breast feeding. Female subjects of non-childbearing potential must be surgically sterile (i.e., bilateral tubal ligation or removal of both ovaries and/or uterus at least 6 months prior to dosing) OR naturally postmenopausal (spontaneous cessation of menses) for at least 24 consecutive months prior to dosing, with a follicle stimulating hormone (FSH) level at Screening of =40 mIU/mL; - Willing and able to comply with clinic visits and study-related procedures; - voluntarily participating in this clinical trial, understanding the study procedures and providing signed informed consent. Exclusion Criteria: - Known history of Grade 3 or Grade 4 hypersensitivity to any components (antibody-drug conjugate [ADC], total antibody, unconjugated toxin) of the SHR-A1403 product, or sensitivity to humanized monoclonal antibody products); - Any radiation or surgery within 4 weeks prior to the first dose of SHR-A1403, except for minor palliative intent(this is to be discussed with sponsor); - Unresolved toxicities from previous anticancer therapy,defined as toxicities not yet resolved to NCI CTCAE (current version) grade =1 at baseline (other than alopecia and other tolerable AEs upon discussion with sponsor) . Subjects with chronic grade 2 toxicities may be eligible at the discretion of the investigator and discussion with sponsor; - Central nervous system tumors or active central nervous system (CNS) metastasis by imaging diagnosis; - Cardiac disease (New York Heart Association [NYHA] classes II-IV) including myocardial infarction,unstable angina, congestive heart failure, or cardiac arrhythmia requiring treatment within a minimum 6 months before enrollment; - Active HBV and HCV infection (HBV virus copy number>50 IU/mL, HCV virus RNA positive); - History of immunodeficiency including seropositivity for human immunodeficiency virus (HIV) or other acquired or congenital immune- deficient disease, or history of any organ transplantation; - Any other medical(such as severe hypertension, diabetes, thyroid disease, etc.) or psychiatric or social condition deemed by the investigator to be likely serious hazards to a subject's rights, safety, welfare, or interfere with ability to sign informed consent, cooperate and participate in the study, interpret the results. |
Country | Name | City | State |
---|---|---|---|
China | Shanghai Cancer Center, Fudan University | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Jiangsu HengRui Medicine Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The assessment of Treatment-related Adverse Events of SHR-A1403 in subjects with advanced solid tumors | Assessment of the incidence and severity of treatment-related Advanse events will be collected and analysed in all subjects who received at least 1 dose of SHR-A1403 with the current version of the NCI CTCAE | up to 24 months | |
Primary | DLT | A DLT is considered at AE related to study drug unless there is a clear, well-documented, alternative explanation for the toxicity. Severity of AEs are graded according to the current version of the NCI CTCAE for the study, the occurence of the following drug related AEs during the first cycle(1 to 21days from the first infusion) will be considered a DLT by the investigator and SMC. | up to 24 months | |
Primary | MTD | MTD is the highest dose whose toxicity probability was lower or close to the preset target level of toxicity probability (30% in this study) during the DLT observation in the dose escalation of SHR-A1403. | up to 24 months | |
Secondary | Time to peak (Tmax) of serum concentration | Pharmacokinetics profile of SHR-A1403:Time to peak (Tmax) of serum concentration | Up to 24 months | |
Secondary | Maximum serum concentration (Cmax) | Pharmacokinetics profile of SHR-A1403:Maximum serum concentration (Cmax) | Up to 24 months | |
Secondary | Half-life (T1/2) | Pharmacokinetics profile of SHR-A1403:Half-life (T1/2) | Up to 24 months | |
Secondary | Clearance/ bioavailability (CL/F) | Pharmacokinetics profile of SHR-A1403:Clearance/ bioavailability (CL/F) | Up to 24 months | |
Secondary | Apparent volume of distribution/bioavailability (Vd/F) | Pharmacokinetics profile of SHR-A1403:Apparent volume of distribution/bioavailability (Vd/F) | Up to 24 months | |
Secondary | Area under curve (AUC) | Pharmacokinetics profile of SHR-A1403:Area under curve (AUC) | Up to 24 months | |
Secondary | Accumulation index (Rac) | Pharmacokinetics profile of SHR-A1403:Accumulation index (Rac) | up to 24 months | |
Secondary | The assessment of anti-drug antibody | The serum of patients who are administered with intravenous infusion every three weeks (q3w) for a treatment cycle are collected at difinitive time points, Anti-SHR-A1403 antibody will be detected and measured. | up to 24 months | |
Secondary | Preliminary efficacy assessments of SHR-A1403 | Subjects will be assessed every other cycle using RECIST v1.1. | up to 24 months | |
Secondary | C-Met expression levels in blood | The exploratory biomarker, C-Met,from blood samples obtained pre- and post-treatment will be measured. | up to 24 months | |
Secondary | C-Met expression levels in tumor tissue | The exploratory biomarker, C-Met, from tumor tissue samples obtained pre- and post-treatment will be measured. | up to 24 months | |
Secondary | The recommended Phase 2 dose (RP2D) of SHR-A1403 in subjects with advanced solid tumors | When the dose escalation is accomplished, RP2D will be reported by the assessment of safety with CTCAE v4.03. | up to 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT05508100 -
Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT05515185 -
B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors
|
Early Phase 1 | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT02836600 -
A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04890613 -
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
|
Phase 1 | |
Recruiting |
NCT04390737 -
Evaluate the Safety and Clinical Activity of HH2853
|
Phase 1/Phase 2 | |
Recruiting |
NCT05981703 -
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06007482 -
A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT04108676 -
Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects
|
Phase 1 | |
Recruiting |
NCT05798611 -
Study of ART0380 in Patients With Biologically Selected Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05076396 -
PM14 Administered Intravenously to Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06008366 -
A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06054932 -
Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04825392 -
A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06365918 -
Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis
|
Phase 1 | |
Recruiting |
NCT05443126 -
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05461287 -
Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05569057 -
A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma
|
Phase 1 |